Boehringer Ingelheim Ditches Phase II Alzheimer's Program Post author:Sam Post published:February 8, 2018 Post category:BioPharma Another potential treatment for Alzheimer’s disease has been tossed into the rubbish bin. Source: BioSpace You Might Also Like Dicerna Could Pocket $201M in NASH R&D Deal With Boehringer Ingelheim November 1, 2017 InstantLabs Secures Controlling Investment From February 23, 2017 Bay Area's Global Blood Therapeutics Terminates Lung Disease Program October 22, 2017